• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Dynavax Technologies Corporation

    6/5/25 5:21:18 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DVAX alert in real time by email
    DEFA14A 1 d15942ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    Dynavax Technologies Corporation

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rule 14a-6(i)(1) and 0-11.

     

     
     


    This Schedule 14A filing consists of the following email distributed by Dynavax Technologies Corporation (the “Company”) to its employees in connection with the Company’s 2025 Annual Meeting of Stockholders. The email was first used or made available after 3:20pm ET on June 5, 2025.

    Subject: Important Reminder Ahead of June 11 Annual Meeting

    Team,

    Our Annual Meeting of Stockholders is less than one week away on June 11. For those of you who are Dynavax stockholders and have already voted – thank you! For those of you who haven’t yet voted, there is still time and we encourage you to do so as soon as possible. I have pasted some instructions below for your reference and if you have any questions, please contact our proxy solicitor, MacKenzie Partners, who can answer any questions you have at 1 (800) 322-2885.

    Over the last few days, three independent proxy advisory firms have issued reports and provided voting recommendations to institutional shareholders. We received full support from two firms (ISS and Egan-Jones), which is important recognition of our team, strategy and value we are delivering to our stakeholders, and the third firm (Glass Lewis) split its recommendation. As always, thank you all for your hard work and dedication! Let’s all keep up the great work and energy we bring every day.

    Voting Instructions

     

      •  

    Step 1 – Use the GOLD proxy card from Dynavax. Deep Track’s proxy materials contain a white proxy card that we encourage you to disregard and NOT use to vote. If you have already voted using Deep Track’s white proxy card, you have the right to change your vote and revoke your prior submitted proxy by voting using Dynavax’s gold proxy card or voting instruction form (follow the instructions provided below).

     

      •  

    Step 2 – Cast your vote.

     

      •  

    Proposal #1: The Board recommends that stockholders vote “FOR” all four of Dynavax’s director nominees only – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun. You may mark “FOR” votes for only up to four nominees.

     

      •  

    Proposals #2, #3 and #4: The Board recommends that stockholders vote “FOR” Proposals #2, #3 and #4.

     

      •  

    Proposal #5: The Board recommends that stockholders vote “AGAINST” Proposal #5.

     

    LOGO


      •  

    Step 3 – Submit your vote. You can submit your vote using one of the following four methods, though email, telephone or internet will be the quickest way to do so and will ensure your vote is cast on time. You only have to vote once.

     

      •  

    By mail: Complete, sign, date and return the GOLD proxy card or voting instruction form in the postage-paid envelope provided.

     

      •  

    By internet: The GOLD proxy card or voting instruction form you received includes a URL to submit your votes electronically. Then, follow the instructions on the voting website. You will be required to provide the unique control number on your proxy card or voting instruction form. If you want to vote by internet, you must submit your vote by 8:59 p.m. PT on June 10.

     

      •  

    By telephone: Please call our proxy solicitor, MacKenzie Partners, at 1 (800) 322-2885. You will be required to provide the unique control numbers on your proxy card or voting instruction form.

     

      •  

    By e-mail: If you received proxy materials via e-mail, the e-mail message included a link with instructions on how to vote. You will be required to provide the unique control numbers on your proxy card or voting instruction form.

    If you hold Dynavax shares in more than one account (e.g., through our employee savings plan, in registered name or through a personal bank or brokerage account), you’ll receive separate GOLD proxy cards or voting instruction forms for each account. To ensure all your shares are represented, please submit your vote for each account in which you hold shares.

    Thank you,

    Ryan

    Forward-Looking Statements

    This communication contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements. Forward-looking statements can generally be identified by the use of words such as “continue,” “expect,” “will,” “plan,” “would” and similar expressions, or the negatives thereof, or they may use future dates. Forward-looking statements made in this document include statements regarding delivering value for our stockholders, our business strategy and long-term performance. Actual results may differ materially from those set forth in this communication due to the risks and uncertainties inherent in our business, including, the risk that circumstances surrounding or leading up to our 2025 Annual Meeting may change risks related to the implementation of our long-term growth objectives, as well as other risks detailed in the “Risk Factors” section of our Quarterly Report on Form 10-Q for the three months ended March 31, 2025 and any periodic filings made thereafter, as well as discussions of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date hereof, are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax’s website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.

    Important Additional Information and Where to Find It

    On April 17, 2025, the Company filed a definitive proxy statement on Schedule 14A (the “Proxy Statement”) and form of accompanying GOLD proxy card with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its 2025 Annual Meeting and its solicitation of proxies for the Company’s director nominees and for other matters to be voted on. The Company may also file other relevant documents with the SEC regarding its solicitation of proxies for the 2025 Annual Meeting. This communication is not a substitute for any proxy statement or other document that the Company has filed or may file with the SEC in connection with any solicitation by the Company. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT, ACCOMPANYING GOLD PROXY CARD AND OTHER RELEVANT DOCUMENTS FILED WITH, OR FURNISHED TO, THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION. Stockholders may obtain a copy of the Proxy Statement, accompanying GOLD proxy card, any amendments or supplements to the Proxy Statement and any other relevant documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge at the Company’s website at https://investors.dynavax.com/sec-filings.


    Certain Information Regarding Participants

    This communication is neither a solicitation of a proxy or consent nor a substitute for any proxy statement or other filings that may be made with the SEC. The Company, its directors, its director nominees and certain of its executive officers and employees may be deemed to be participants in the solicitation of proxies for the 2025 Annual Meeting. Information regarding the names of such persons and their respective direct or indirect interests in the Company, by securities holdings or otherwise, is available in the Proxy Statement, which was filed with the SEC on April 17, 2025, including in the sections captioned “Compensation Discussion and Analysis,” “Summary Compensation Table,” “Grants of Plan Based Awards,” “Outstanding Equity Awards at Fiscal Year End,” “Pay Ratio Disclosure,” “Director Compensation,” “Certain Transactions,” “Security Ownership of Certain Beneficial Owners and Management,” and “Supplemental Information Regarding Participants in the Solicitation.” To the extent that the Company’s directors and executive officers have acquired or disposed of securities holdings since the applicable “as of” date disclosed in the Proxy Statement, such transactions have been or will be reflected on Statements of Changes in Ownership of Securities on Form 4 or Initial Statements of Beneficial Ownership of Securities on Form 3 filed with the SEC. These documents are or will be available free of charge at the SEC’s website at www.sec.gov.

    Get the next $DVAX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVAX

    DatePrice TargetRatingAnalyst
    2/11/2025$15.00 → $12.00Neutral → Sell
    Goldman
    2/1/2024$20.00Neutral
    Goldman
    9/27/2022$22.00Mkt Outperform
    JMP Securities
    1/6/2022$38.00Buy
    Goldman
    12/29/2021$23.00 → $28.00Buy
    HC Wainwright & Co.
    8/31/2021$20.00 → $23.00Buy
    HC Wainwright & Co.
    8/6/2021$19.00Buy
    Goldman Sachs
    8/5/2021$16.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Silvernail Lauren P was granted 1,439 shares, increasing direct ownership by 17% to 10,075 units (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    6/13/25 5:55:43 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kisner Daniel L was granted 5,758 shares, increasing direct ownership by 33% to 23,329 units (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    6/13/25 5:53:29 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Myers Scott Dunseth was granted 5,758 shares, increasing direct ownership by 23% to 31,204 units (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    6/13/25 5:51:37 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    SEC Filings

    View All

    SEC Form 10-Q filed by Dynavax Technologies Corporation

    10-Q - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

    8/7/25 4:14:43 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dynavax Technologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

    8/7/25 4:03:54 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dynavax Technologies Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders

    8-K - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

    6/17/25 7:30:35 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dynavax Reports Second Quarter 2025 Financial Results

    Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growthRefines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million, from $305 to $325 millionTop-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in August 2025Completed dosing in Part 1 of Phase 1/2 trial of pandemic influenza adjuvant programConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Aug. 7, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update

    8/7/25 4:00:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

    EMERYVILLE, Calif., July 29, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2025 financial results on Thursday, August 7, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investo

    7/29/25 4:02:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting

    EMERYVILLE, Calif., June 11, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company's 2025 Annual Meeting of Stockholders ("Annual Meeting"), Dynavax stockholders have voted to elect all four of its director nominees – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun – to the Company's Board of Directors. Dynavax issued the following statement:

    6/11/25 11:01:00 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dynavax downgraded by Goldman with a new price target

    Goldman downgraded Dynavax from Neutral to Sell and set a new price target of $12.00 from $15.00 previously

    2/11/25 7:05:05 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Dynavax with a new price target

    Goldman initiated coverage of Dynavax with a rating of Neutral and set a new price target of $20.00

    2/1/24 6:20:13 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on Dynavax with a new price target

    JMP Securities initiated coverage of Dynavax with a rating of Mkt Outperform and set a new price target of $22.00

    9/27/22 7:39:04 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Financials

    Live finance-specific insights

    View All

    Dynavax Reports Second Quarter 2025 Financial Results

    Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growthRefines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million, from $305 to $325 millionTop-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in August 2025Completed dosing in Part 1 of Phase 1/2 trial of pandemic influenza adjuvant programConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Aug. 7, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update

    8/7/25 4:00:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

    EMERYVILLE, Calif., July 29, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2025 financial results on Thursday, August 7, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investo

    7/29/25 4:02:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs

    Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growthTop-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025New pandemic influenza adjuvant program and Lyme disease vaccine programs planned to enter clinical development in 2025 and 2027, respectively Conference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., May 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended March 31, 2025.

    5/6/25 4:01:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Leadership Updates

    Live Leadership Updates

    View All

    Deep Track Capital Comments on ISS Recommendation

    Strongly Disagrees with Recommendation and Believes ISS Ignored Key Issues in Its Incomplete Analysis ISS Has Chosen Not to Hold the Board Accountable for Its Underperformance in Recent Years, Heplisav's Waning Market Share Growth and Poor Corporate Governance Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax", "DVAX" or the "Company"), with ownership of approximately 14.82% of the Company's outstanding shares, today issued the following statement in response to a report issued by Instit

    5/23/25 6:12:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

    ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleading Supplemental Materials Urges Stockholders to Follow ISS Recommendation and Vote "FOR" ALL Four of Dynavax's Highly Qualified Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., May 23, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that leading independent proxy advisory firm, Institutional Shareholder Services ("ISS

    5/23/25 1:44:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    /C O R R E C T I O N -- Dynavax Technologies/

    In the news release, Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum, issued 07-May-2025 by Dynavax Technologies over PR Newswire, we are advised by the company that the second paragraph, second sentence of the stockholder letter should read "Dynavax has generated over $900 million of stockholder value, returning over 62% versus the S&P Biotechnology Select Industry Index's return of -7%[2]." rather than "Dynavax has generated approximately $1 billion of stockholder value, returning over 104% versus the S&P Biotechnology Select Industry Index's return of only 14%[2]." as originally issued inadvertently. The complete, corre

    5/7/25 4:45:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Dynavax Technologies Corporation

    SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    11/14/24 12:18:08 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dynavax Technologies Corporation

    SC 13D/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    10/24/24 4:06:57 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dynavax Technologies Corporation

    SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    10/16/24 9:37:13 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care